Sign In

Liliane Chamas, PhD

Health Tech Investor and Venture Builder

Liliane Chamas, PhD, is a prominent figure in the fields of genetics research and digital health innovation. Currently serving as a Board Member at Ground Truth Labs, she brings over a decade of experience to the organization, focusing on deploying digital solutions to address health challenges globally.12

Educational Background

Dr. Chamas completed her PhD in Human Genetics at the University of Oxford, where she was recognized as a Canadian Rhodes Scholar. Her academic journey has equipped her with a strong foundation in genetics and health systems.23

Professional Experience

Before her role at Ground Truth Labs, Liliane worked extensively with the World Health Organization, where she evaluated technologies aimed at improving healthcare access for indigenous and refugee communities. Additionally, she coordinated global guidance for digital health initiatives in areas such as diabetes and hypertension.2

Her experience also includes serving as a Global Health Policy Fellow at Imperial College London, where she contributed to reforming medical education in Myanmar. Furthermore, as Deputy Head of the NHS/Foreign Office joint unit for the UK Prosperity Fund, she led strategies to facilitate technology exchange and healthcare best practices across various regions, including Latin America and Southeast Asia.23

Current Roles

In addition to her position at Ground Truth Labs, Dr. Chamas is involved with Oxford Science Enterprises, focusing on early-stage healthcare technology ventures. She also holds board positions at other organizations such as Amber Therapeutics.14

Through her diverse roles, Liliane Chamas exemplifies a commitment to leveraging technology for improved health outcomes and innovative solutions in the healthcare sector.

Highlights

Jun 10 · linkedin

It’s an enormous privilege to have been part of Amber Therapeutics growth from inception to now securing USD100m in Series A financing from leading US/UK investors.

This investment marks a major step towards disrupting the treatment paradigm for patients with mixed urinary incontinence.

Amber will now push towards FDA approval for its singular adaptive neuromodulation therapy for both urge and stress incontinence off the back of its successful first-in-human results.

This achievement is a huge testament to the neuroengineering ingenuity of Prof Tim Denison, Ph.D., clinical excellence of Prof Charles Knowles and Prof Stefan De Wachter and their teams, under the indefatigable leadership of CEO Aidan Crawley.

As a founding board member, I can’t wait to work with our new stellar board Tiffany Le Ali Behbahani New Enterprise Associates (NEA) Kevin Chu F-Prime Capital Caroline Gaynor Lightstone Ventures Murielle Thinard McLane Intuitive Ventures.

Our team at OSE, Heather Roxborough Tony Besse Sive Ozer Alex Hammacher and myself have and will proudly continue to support Amber on its exciting journey forward!

Related Questions

What are some of Liliane Chamas' most notable achievements in genetics research?
How has Liliane Chamas' work at the World Health Organization impacted global health policies?
What specific digital health innovations has Liliane Chamas been involved in?
How did Liliane Chamas' role at Oxford Sciences Innovation differ from her role at Ground Truth Labs?
What are Liliane Chamas' main responsibilities as a board member at Ground Truth Labs?
Liliane Chamas, PhD
Liliane Chamas, PhD, photo 1
Liliane Chamas, PhD, photo 2
Add to my network

Location

United Kingdom